Gibbons and Venable filed a pair of complaints Wednesday on behalf of Bausch & Lomb involving federal trademark ... Nutriceuticals also sell an eye health dietary supplement called NutriTear ...

Of note, Bausch + Lomb is the eye-care subsidiary of Bausch Health Companies, which was formerly known as Valeant Pharmaceuticals. Valeant got into trouble nearly a decade ago after using debt to ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Bausch + Lomb, one of the world’s largest contact lens suppliers, is exploring a sale as a way to clean ...

this is a good opportunity for the market to finally realize what we have in Bausch + Lomb. I would keep a close eye on the potential buyout rumors because that is the most obvious means to see an ...

Bausch + Lomb Corp. shares rose the most ever following a report that the eye care company is considering selling itself to disentangle from its debt-laden parent company. The Financial Times ...

The stock of eyecare company Bausch + Lomb Corp. was up 14%on Monday, after the Financial Times reported that the company is considering selling itself as a way to extricate itself from its ...

lenses for the first satellite pictures of the moon . . . products for eye surgery . . . and the first soft contact lenses. The relationship between Bausch & Lomb and the Rochester Institute of ...

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care ...

Investing.com -- Bausch + Lomb (NYSE:BLCO) is exploring a potential ... the steep valuation discount between BLCO and its closest eye care peers,” said analysts from Wells Fargo in a note.

Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) and keeping the price target at $23.00. Larry Biegelsen has given his Buy ...

Bausch + Lomb BLCO shares ended the last trading session ... So, make sure to keep an eye on BLCO going forward to see if this recent jump can turn into more strength down the road.

Eyecare company is working with Goldman Sachs on a deal that would extricate it from its indebted parent, the Financial Times reported The stock of eyecare company Bausch + Lomb Corp. was up 14%on ...